We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.83 | -0.64% | 129.55 | 131.51 | 129.33 | 131.12 | 6,644,802 | 21:15:22 |
By Colin Kellaher
Merck & Co. on Monday reported positive results from a Phase 1 study evaluating the safety, tolerability and pharmacokinetics of its investigational islatravir subdermal implant for the prevention of HIV-1 infection.
The Kenilworth, N.J., drugmaker said the data support the potential for a once-yearly dosing regimen for islatravir using a subdermal implant for pre-exposure prophylaxis, or "PrEP," of HIV-1 infection.
Merck said the implant achieved active drug concentrations above the pre-specified threshold at 12 weeks across the three doses of islatravir studied and is projected to provide drug concentrations likely above threshold for one year at the highest dose.
Based on the findings, Merck said it plans to launch a Phase 2 trial to further explore the potential of a subdermal implant containing islatravir as a long-acting option for PrEP for up to 12 months.
The company is studying islatravir across a variety of doses, formulations and frequencies for both the treatment of HIV-1 infection in combination with other antiretroviral agents and for the prevention of HIV-1 infection as a single agent.
Shares of Merck rose nearly 3% in midday trading Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 08, 2021 12:17 ET (17:17 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions